Novel Deposition Technique for Fabricating Films with Customized Thickness Profiles.

This study introduces a novel deposition technique capable of depositing thin films with any arbitrary thickness profile. The apparatus consists of a fixed shadow mask and a rotating sample carrier plate. The shadow mask features a specifically designed opening curve that corresponds to the particular thickness profile of the deposited film.

Long-Term Determinants of Depression Mood: A 19-Year Follow Up of 2344 Middle-Aged and Older Adults.

This study explores depression changes and influencing factors in middle-aged and older individuals, focusing on different cognitive function states. This cohort study uses panel data from seven waves of the nationally representative Taiwan Longitudinal Study on Aging (1996-2015) with 2344 participants aged 50 or above. Data analysis was conducted from 25 January 2023 to 4 May 2023.

Multi-channel learning for integrating structural hierarchies into context-dependent molecular representation.

Reliable molecular property prediction is essential for various scientific endeavors and industrial applications, such as drug discovery. However, the data scarcity, combined with the highly non-linear causal relationships between physicochemical and biological properties and conventional molecular featurization schemes, complicates the development of robust molecular machine learning models. Self-supervised learning (SSL) has emerged as a popular solution, utilizing large-scale, unannotated molecular data to learn a foundational representation of chemical space that might be advantageous for downstream tasks.

Efficacy and Safety of PARP Inhibitors in Prostate Cancer: An Umbrella Review of Systematic Reviews and Meta-analyses.

Prostate cancer is a significant cause of cancer-related deaths in men. Poly (ADP-ribose) polymerase inhibitors (PARPi) have been shown to improve progression-free survival, especially in patients with BRCA1/2 mutations and deficiencies in homologous recombination repair (HRR). We conducted systematic reviews and meta-analyses and found that PARPi, combined with androgen receptor inhibitors, significantly improved overall survival (OS) and progression-free survival (PFS) in BRCA1/2-mutant and HRR-deficient patients.